- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
Chapter 2 |
35 |
|
|
Urological investigations
Urine examination 36 Urine cytology 38
Prostatic specific antigen (PSA) 39 Radiological imaging of the urinary tract 40 Uses of plain abdominal radiography (KUB
X-ray—kidneys, ureters, bladder) 42 Intravenous pyelography (IVP) 44 Other urological contrast studies 48
Computed tomography (CT) and magnetic resonance imaging (MRI) 50
Radioisotope imaging 52 Uroflowmetry 54
Post-void residual urine volume measurement 58 Cystometry, pressure-flow studies, and
videocystometry 60
36 CHAPTER 2 Urological investigations
Urine examination
Dipstick testing
Analysis for pH, blood, protein, glucose, and white cells can be done with dipstick testing.
pH
Urinary pH varies between 4.5 and 8, averaging between 5.5 and 6.5.
Blood
Normal urine contains <3 RBCs per high-powered field (HPF) (~1000 erythrocytes/mL of urine; upper limit of 5000–8000 erythrocytes/mL). Positive dipstick for blood indicates the presence of hemoglobin in the urine.
Hemoglobin has a peroxidase-like activity and causes oxidation of a chromogen indicator, which changes color when oxidized. Sensitivity of urine dipsticks for identifying hematuria (>3 RBCs/HPF) is >90%; specificity is lower (i.e., a higher false-positive rate with the dipstick), due to contamination with menstrual blood or dehydration (concentrates what RBCs are normally present in urine).
Hematuria due to a urological cause does not elevate urinary protein. Hematuria of nephrological origin often occurs in association with casts, and there is almost always significant proteinuria.
Protein
Normal, healthy adults excrete about 80–150 mg of protein per day in their urine (normal protein concentration <20 mg/dL). Proteinuria suggests the presence of renal disease (glomerular, tubulointerstitial, renal vascular) or multiple myeloma, but it can occur following strenuous exercise. A dipstick test is based on a tetrabromophenol blue dye color change (green color develops in the presence of protein of >20 mg/dL).
White blood cells
Leukocyte esterase activity detects the presence of white blood cells (WBCS) in the urine. Leukocyte esterase is produced by neutrophils and causes a color change in a chromogen salt on the dipstick. Not all patients with bacteriuria have significant pyuria.
False negatives are due to concentrated urine, glycosuria, presence of urobilinogen, and consumption of large amounts of ascorbic acid. False positives are due to contamination.
Nitrite testing
Nitrites in the urine suggest the possibility of bacteriuria. They are not normally found in the urine. Many species of gram-negative bacteria can convert nitrates to nitrites, and these are detected in urine by a reaction with the reagents on the dipstick that form a red azo dye.
The specificity of the nitrite dipstick for detecting bacteriuria is >90% (false-positive nitrite testing is contamination). Sensitivity is 35–85% (i.e., lots of false negatives); it is less accurate in urine containing fewer than 105 organisms/mL.
URINE EXAMINATION 37
Cloudy urine that is positive for WBCs and is nitrite positive is very likely to be infected.
Urine microscopy
Red blood cell morphology
This is determined by phase-contrast microscopy. RBCs derived from the glomerulus are dysmorphic (they have been distorted by their passage through the glomerulus). RBCs derived from tubular bleeding (tubulointerstitial disease) and those from lower down the urinary tract (i.e., urological bleeding from the renal pelvis, ureters, or bladder) have a normal shape. Glomerular bleeding is suggested by the presence of dysmorphic RBCs, RBC casts, and proteinuria.
Casts
A cast is a protein coagulum (principally, Tamm–Horsfall mucoprotein derived from tubular epithelial cells) formed in the renal tubule and “cast” in the shape of the tubule (i.e., long and thin). The protein matrix traps tubular luminal contents. If the cast contains only mucoproteins it is called a hyaline cast. It is seen after exercise, heat exposure, and in pyelonephritis or chronic renal disease.
RBC casts contain trapped erythrocytes and are diagnostic of glomerular bleeding, most often due to glomerulonephritis. WBC casts are seen in acute glomerulonephritis, acute pyelonephritis, and acute tubulointerstitial nephritis.
Crystals
Specific crystal types may be seen in urine and help diagnose underlying problems (e.g., cystine crystals establish the diagnosis of cystinuria). Calcium oxalate, uric acid, and cystine are precipitated in acidic urine. Crystals precipitated in alkaline urine include calcium phosphate and tri- ple-phosphate (struvite).
38 CHAPTER 2 Urological investigations
Urine cytology
Urine collections for cytology
Exfoliated cells lying in urine that has been in the bladder for several hours (e.g., early morning specimens) or in a urine specimen that has been allowed to stand for several hours are degenerate. Such urine specimens are not suitable for cytological interpretation.
Cytological examination can be performed on bladder washings (using normal saline) obtained from the bladder at cystoscopy (or following catheterization) or from the ureter (via a ureteric catheter or ureteroscope). The urine is centrifuged, and the specimen obtained is fixed in alcohol and stained by the Papanicolaou technique.
Normal urothelial cells are shed into the urine. Under microscopy their nuclei appear regular and monomorphic (diffuse, fine chromatin pattern, single nucleolus).
Causes of a positive cytology report (i.e., abnormal urothelial cells seen—high nuclear–cytoplasmic ratio, hyperchromatic nuclei, prominent nucleoli) include the following:
•Urothelial malignancy (transitional cell carcinoma [TCC], squamous cell carcinoma, adenocarcinoma)
•Previous radiotherapy (especially if within the last 12 months)
•Previous cytotoxic drug treatment (especially if within the last 12 months; e.g., cyclophosphamide, busulphan, cysclosporin)
•Urinary tract stones
Renal adenocarcinoma (clear cell cancer of the kidney) usually does not exfoliate abnormal cells, though occasionally clusters of clear cells may be seen, suggesting the diagnosis.
High-grade urothelial cancer and carcinoma in situ exfoliate cells that look very abnormal, and usually the cytologist is able to indicate that there is a high likelihood of a malignancy. Low-grade bladder TCC exfoliates cells that look very much like normal urothelial cells. The difficulty arises where the cells look abnormal, but not that abnormal—here the likelihood that the cause of the abnormal cytology is a benign process is greater.
Sensitivity and specificity of positive urine cytology for detecting TCC of the bladder depend on the definition of positive—if only obviously malignant or highly suspicious samples are considered positive, then the specificity will be high. Urine cytology may be negative in as many as 20% of high-grade cancers.
If “atypical cells” are included in the definition of abnormal, the specificity of urine cytology for diagnosing urothelial cancer will be relatively poor (relatively high number of false positives) because many cases will have a benign cause (stones, inflammation).
PROSTATIC SPECIFIC ANTIGEN (PSA) 39
Prostatic specific antigen (PSA)
PSA is a 34KD glycoprotein enzyme produced by the columnar acinar and ductal prostatic epithelial cells. It is a member of the human kallikrein family and its function is to liquefy the ejaculate, enabling fertilization. PSA is present in both benign and malignant cells, although the expression of PSA tends to be reduced in malignant cells and may be absent in poorly differentiated tumors. Large amounts are secreted into the semen, and small quantities are found in the urine and blood.
The function of serum PSA is unclear, although it is known to liberate the insulin-like growth factor type 1 (IGF-1) from one of its binding proteins. 75% of circulating PSA is bound to plasma proteins (complexed PSA) and metabolized in the liver, while 25% is free and excreted in the urine. Complexed PSA is stable, bound to A1-antichymotrypsin and A2- macroglobulin. Free PSA is unstable, recently found to consist of two isoforms: pro-PSA is a peripheral zone precursor, apparently elevated in the presence of prostate cancer, and BPSA is the transition zone precursor and associated with benign prostatic hyperplasia (BPH).
The half-life of serum PSA is 2.2 days. A prostate biopsy is often recommended for men with a PSA > 2.5 ng/mL, though this varies with age. Table 2.1 shows a published age-specific normal range (95th percentile).
In the absence of prostate cancer, serum PSA concentrations also vary physiologically, according to race and prostate volume.
Indications for checking serum PSA
•Patient request, following counseling
•Lower urinary tract symptoms
•Abnormal digital rectal examination
•Progressive bone pain, especially back pain
•Unexplained anemia, anorexia, or weight loss
•Spontaneous thromboembolism or unilateral leg swelling
•Monitoring of prostate cancer patients
Table 2.1 Age-adjusted normal range for PSA
Age range (years) |
Normal PSA range (ng/mL) |
40–49 |
<2.5 |
50–59 |
<3.5 |
60–69 |
<4.5 |
>70 |
<6.5 |
|
|